The estimated Net Worth of John A Orwin is at least $909 Tysiąc dollars as of 15 June 2024. Mr Orwin owns over 2,035 units of Atreca Inc stock worth over $183 and over the last 11 years he sold BCEL stock worth over $45,708. In addition, he makes $863,516 as Pres i CEO & Director at Atreca Inc.
Mr has made over 8 trades of the Atreca Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 2,035 units of BCEL stock worth $183 on 15 June 2024.
The largest trade he's ever made was selling 22,951 units of Atreca Inc stock on 1 September 2023 worth over $8,492. On average, Mr trades about 1,775 units every 85 days since 2013. As of 15 June 2024 he still owns at least 2,035 units of Atreca Inc stock.
You can see the complete history of Mr Orwin stock trades at the bottom of the page.
John A. Orwin is the Pres, CEO & Director at Atreca Inc.
As the Pres i CEO & Director of Atreca Inc, the total compensation of Mr Orwin at Atreca Inc is $863,516. There are no executives at Atreca Inc getting paid more.
Mr Orwin is 56, he's been the Pres i CEO & Director of Atreca Inc since . There are 1 older and 2 younger executives at Atreca Inc. The oldest executive at Atreca Inc is Dr. Tito A. Serafini Ph.D., 58, who is the Founder, Chief Strategy Officer & Director.
John's mailing address filed with the SEC is C/O ANAPTYSBIO, INC., 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121.
Over the last 5 years, insiders at Atreca Inc have traded over $4,571,843 worth of Atreca Inc stock and bought 6,001 units worth $76,740 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro... oraz Harbor Master Investors (Ca.... On average, Atreca Inc executives and independent directors trade stock every 20 days with the average trade being worth of $991. The most recent stock trade was executed by John A Orwin on 11 April 2024, trading 1 units of BCEL stock currently worth $0.
atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. with its immune repertoire capture™ (irc™) technology, atreca has an unparalleled insight into how cancer patients’ immune responses can drive better clinical outcomes. atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today’s patients is the key to creating a new generation of therapies. atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health. if you are interested in becoming part of the atreca team, our open positions can be found at: http://www.atreca.com/careers/
Atreca Inc executives and other stock owners filed with the SEC include: